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Rhizomelic chondrodysplasia punctata (RCDP) is a group of disorders with overlapping clinical features including rhizomelia, chondro-
dysplasia punctata, coronal clefts, cervical dysplasia, congenital cataracts, profound postnatal growth retardation, severe intellectual
disability, and seizures. Mutations in PEX7, GNPAT, and AGPS, all involved in the plasmalogen-biosynthesis pathway, have been
described in individuals with RCDP. Here, we report the identification of mutations in another gene in plasmalogen biosynthesis, fatty
acyl-CoA reductase 1 (FAR1), in two families affected by severe intellectual disability, early-onset epilepsy, microcephaly, congenital
cataracts, growth retardation, and spasticity. Exome analyses revealed a homozygous in-frame indel mutation (c.495_507delinsT
[p.Glu165_Pro169delinsAsp]) in two siblings from a consanguineous family and compound-heterozygous mutations (c.[787C>T];
[1094A>G], p.[Arg263*];[Asp365Gly]) in a third unrelated individual. FAR1 reduces fatty acids to their respective fatty alcohols for
the plasmalogen-biosynthesis pathway. To assess the pathogenicity of the identified mutations, we transfected human embryonic kid-
ney 293 cells with plasmids encoding FAR1 with either wild-type or mutated constructs and extracted the lipids from the cells. We
screened the lipids with gas chromatography andmass spectrometry and found that all three mutations abolished the reductase activity
of FAR1, given that no fatty alcohols could be detected. We also observed reduced plasmalogens in red blood cells in one individual to a
range similar to that seen in individuals with RCDP, further supporting abolished FAR1 activity. We thus expand the spectrum of clinical
features associated with defects in plasmalogen biosynthesis to include FAR1 deficiency as a cause of syndromic severe intellectual
disability with cataracts, epilepsy, and growth retardation but without rhizomelia.Peroxisomes are eukaryotic membrane-bound subcellular
organelles that catalyze a large number of critical meta-
bolic reactions, including peroxisomal fatty-acid b-oxida-
tion, plasmalogen (ether phospholipid) biosynthesis,
fatty-acid a-oxidation, and glyoxylate detoxification.1
Their crucial role in human health is exemplified by the
increasing number of genetic disorders resulting from de-
fects in peroxisomal metabolism, including peroxisomal
biogenesis (e.g., Zellweger syndrome [MIM 214100]) and
peroxisome function (e.g., rhizomelic chondrodysplasia
punctata [RCDP1 (MIM 215100), RCDP2 (MIM 222765),
and RCDP3 (MIM 600121)]).1 In our study, we focused
on the plasmalogen-biosynthesis pathway in peroxisomes.
Defects in plasmalogen synthesis have been described
and lead to low levels of plasmalogens and to symptoms
of RCDP.2–4 Low levels of plasmalogens were described
in other peroxisomal disorders, such as severe forms of
Zellweger syndrome, and also in more common neurode-
generative disorders, such as Alzheimer disease (MIM
104300) and trisomy 21 (MIM 190685). Nevertheless,
plasmalogen deficiencies in these disorders have been
implicated as a secondary effect.2,5–10
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events,2,11,12 and as precursors for the platelet-activating
factor and cannabinoid receptor ligands.13,14 Plasmalogen
synthesis is a multistep process that involves several en-
zymes. The first few steps take place in the peroxisome,
and final processing occurs in the endoplasmic reticulum
(ER).2,12,15 Mutations in three genes, PEX7 (peroxisomal
biogenesis factor 7 [MIM 601757]), GNPAT (glycerone-
phosphate O-acyltransferase [MIM 602744]), and AGPS
(alkylglycerone phosphate synthase [MIM 603051]), all
involved in plasmalogen synthesis in the peroxisome,
lead to RCDP1, RCDP2, and RCDP3, respectively.16–20
RCDP is characterized by decreased levels of plasmalogens
in red blood cells, rhizomelia, chondrodysplasia punctata,
coronal clefts, cervical dysplasia, congenital cataracts, pro-
found postnatal growth retardation, severe intellectual
disability, cerebellar atrophy, and seizures. Although
most affected children do not survive the first decade of
life, a milder phenotype with variable rhizomelia, less
growth retardation and developmental delays, congenital
cataracts, and sometimes cerebellar hypoplasia has been
reported.21–23
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Figure 1. Pedigrees and Pictures of Affected Individuals
(A and B) Individual V-2 from family A suffers from severe intellectual disability, early-onset epilepsy, spasticity, andmicrocephaly and is
slightly dysmorphic with a long philtrum, high-arched eyebrows, large ears, and a mildly hypoplastic and flattened nasal root.
(C) Pedigree of family A. The parents are first-degree cousins once removed.
(D–F) Individual II-1 from family B is shown at 2 years of age (D) and at 19 years of age (E and F). He has growth failure, seizures, devel-
opmental delay, and only minor dysmorphic features of hypertelorism, ptosis, facial asymmetry, a short nose, a long smooth philtrum,
high-arched eyebrows (evident at the younger age), and a thin upper lip. By 19 years of age, he has some coarsening of his facial features
and has developed seizures that are progressively difficult to control and spastic quadriparesis with neuroregression and encephalopathy.
(G) Pedigree of family B. The parents are not related.acyl-CoAs to their respective fatty alcohols and is therefore
a critical enzyme in plasmalogen biosynthesis.24,25 We
show that mutations in FAR1 result in an autosomal-
recessive peroxisomal disorder of severe, syndromic intel-
lectual disability with congenital cataracts, growth retarda-
tion, and epilepsy but without rhizomelia or the skeletal
changes that are seen in individuals with RCDP.
This study was approved by the ethics committees of the
Universities of Bonn and Erlangen-Nuremberg in Germany
and the University of Calgary in Canada. Informed written
consent was obtained from all examined individuals or
their guardians.
Family A is of Syrian descent and has two affected chil-
dren of consanguineous parents (Figure 1). The affected
female (individual V-1; Figure 1) was born in the seventh
month of pregnancy, and the placenta had calcifications.
She was hypotonic in the neonatal period, and at the age
of 13 months she developed epileptic seizures that were
controlled withmedication. She was last assessed at 5 years
and 3 months of age, at which time she had profound
intellectual disability and only rudimentary interaction
with her family. She had significant microcephaly with a
head circumference of 44 cm (6.6 SDs), weighed 11 kg
(4.8 SDs), and appeared small for her age. The examining
clinical geneticist did not see obvious cataracts, but there
was no examination by an ophthalmologist, so smallerThe Americancataracts have not been excluded. The affected male
(individual V-2; Figure 1) was born at term without any
complications. Shortly thereafter, a bilateral congenital
cataract was diagnosed and required surgical removal. In
the neonatal period, he was hypotonic, which later pro-
gressed to spasticity of the upper and lower extremities.
At the age of 13 months, he developed epileptic seizures
that were also controlled with medication. At the time of
assessment, he was 3 years and 7 months old and had
profound intellectual disability and only rudimentary
interaction with his family. He had significant micro-
cephaly with a head circumference of 40.5 cm (8.7 SDs)
and was small for his age. Investigations of individual
V-2 from family A included a normal karyotype, no evi-
dence of congenital infections, normal amino acid con-
centrations, normal blood gases and electrolytes, and no
hints of a mitochondrial or metabolic disorder. He had a
normal ultrasound examination of the heart and abdomen
and a normal computed-tomography scan of the brain at
the age of 5 months. Nevertheless, brain MRI at the age
of 3 years and 10 months showed a Dandy-Walker variant.
Family B has a single affected male (individual II-1;
Figure 1) born to a healthy 32-year-old female after an
uncomplicated pregnancy. His birth weight was 2.865 kg,
and apart from being born with cryptorchidism, he had
no major medical problems. This individual is now 19Journal of Human Genetics 95, 602–610, November 6, 2014 603
Figure 2. MRI Pictures and X-Rays of Individual II-1 from Family B
(A–D) MRI of individual II-1. Axial T2-weighted images obtained at 9 years of age (A) and again at 15 years of age (B) show increased
signal intensity diffusely but more prominently in the posterior periventricular and peritrigonal regions bilaterally. There is subtle
evidence of progression of these white-matter changes over time. (C) A coronal MP-RAGE-weighted image at 15 years of age shows
prominence of the cerebellar folia consistent with mild to moderate cerebellar atrophy. (D) A sagittal T1-weighted image at 9 years of
age shows mild atrophy of the cerebellum and no evidence of cervical spinal stenosis.
(E–H) Skeletal X-rays of individual II-1 from family B. Skeletal X-rays of individual II-1’s humeri (E and F), left femur (G), and lumbosacral
spine and pelvis (H) were taken at 19 years of age. There is no evidence of rhizomelic shortening of the humeri or femurs. The spine has
decreased intervertebral spaces and tall vertebral bodies. Internal instrumentation was used to treat his scoliosis. There is mild coxa valga
of the femoral necks, and the internal fixation is from his bilateral hip osteotomies.years of age and has a complex medical and neurodevelop-
mental history. He developed early-onset bilateral nuclear
cataracts requiring surgery at 2 years of age. By 6 months
of age, he had started to show significant growth failure
with microcephaly. Currently, his height, weight, and
head circumference are well below the third percentile
(4 to 5 SDs). At 10 months of age, he developed gener-
alized tonic-clonic seizures, which progressed to a more
complex semiology including myoclonic and complex
partial seizures and features of atypical Lennox-Gastaut
syndrome. His seizures have become more difficult to
control with time, and he is now on polytherapy and a
ketogenic diet. Despite these therapies, he still has daily
clinical seizures, and his electroencephalogram shows
subclinical seizures with background slowing consistent
with epileptic encephalopathy. He has developed progres-
sive spastic quadriparesis requiring hamstring and tendon
releases, bilateral hip osteotomies, and internal fixation of
his spine for scoliosis. He has no history of rhizomelia, and
at age 19 he has symmetric short stature without rhizome-
lia. He has never been able to walk or stand unsupported.
Developmentally, he is nonverbal and has a history of604 The American Journal of Human Genetics 95, 602–610, Novembregression in that he has lost the ability to sit, to use
augmentative communication devices or gaze for commu-
nication, and to hold a cup. At 19 years of age, he is drowsy
and difficult to arouse and has profound intellectual
disability. When awake, he shows social interaction and
is calm and gentle. On physical examination, he has severe
growth retardation, microcephaly, ptosis, coarse facial fea-
tures, and generalized spasticity with large- and small-joint
contractures (Figure 1). His MRI shows cerebellar hemi-
spheric and vermian atrophy with progressive multiple
punctate white-matter lesions throughout the cerebral
cortices bilaterally, as well as more confluent white-matter
changes in both subcortical and deep white-matter regions
(Figure 2). There is no evidence of cervical spinal stenosis,
although given the associations between low plasmalogen
levels and multilevel cervical spinal stenosis, repeat and
serial imaging for surveillance purposes are being arranged.
A recent skeletal survey confirmed the absence of rhizome-
lia, and there was no significant evidence of an underlying
bone dysplasia: it showed normal morphology of the long
bones, a mild increase in vertebral body height of the
lumbosacral spine, and a normal pelvis except for milder 6, 2014
coxa valga (Figure 2). Extensive genetic and metabolic in-
vestigations were all normal.
Genotyping and mapping analyses were performed in
family A as previously reported.26 Four candidate regions
(chr4: 111,364,166–113,972,855 bp; chr6: 138,484,928–
144,671,770 bp; chr11: 7,712,660–19,368,171 bp, and
chr15: 75,083,493–79,273,984 bp) homozygous in both
affected children were identified for a total length of 24.6
Mb. DNA from individual V-1 from family A underwent
exome capture and next-generation sequencing on the
SureSelect Human All Exon 50 Mb Kit (Agilent Tech-
nologies) and a SOLiD4 instrument (Life Technologies)
as described previously.27 An average target coverage of
56.73 was obtained, and 58.2% of reads were covered to
a depth of at least 203 and 73.6% were covered to a depth
of at least 53. A total of 36,345 single-nucleotide variants
(SNVs) and 2,563 insertions or deletions (indels) were iden-
tified, and 415 SNVs and 77 indels were neither annotated
in dbSNP nor reported in 1000 Genomes, the NHLBI
Exome Variant Server, or in-house control exomes. Of
these, only one variant, c.495_507delinsT (p.Glu165_
Pro169delinsAsp) in FAR1 (RefSeq accession number
NM_032228.5), was located in a homozygous candidate
region, involved conserved amino acids, and was predicted
to affect the protein sequence. Because the depth of
coverage was low, we repeated sequencing of the coding
sequence (CDS) in the candidate regions (233 genes)
with a custom targeted-capture kit (Agilent Technologies).
We achieved at least 203 coverage for 85.4% of the target
sequence and at least 53 coverage for 90.3% of the
sequence. Combining reads from exome and CDS custom
targeted sequencing, we achieved a mean coverage of
3733 for the CDS within the regions of homozygosity,
and 93.1% of the CDS target region was covered at least
53. No additional candidate variants were identified with
this approach. The FAR1 variant segregated with severe
intellectual disability in the family and was absent in 280
ethnically matched control individuals.
To investigate the cause of sporadic intellectual dis-
ability, we performed trio-based whole-exome sequencing
on individual II-1 from family B and his parents at the
Alberta Children’s Hospital Research Institute Genomics
and Bioinformatics Facility (University of Calgary).
Genomic DNA from affected individual II-1 and his
parents underwent exome enrichment with the Agilent
SureSelect V5 Kit (Agilent Technologies) prior to sequenc-
ing with a 5500xl SOLiD sequencer (Life Technologies).
A total of 31,044 coding variants were identified in the
proband. The average target depth was 1153, and 88% of
target baseswere covered at least 203 and92%were covered
at least 103. After failing to identify any pathogenic de
novo variants, we examined genes in which two rare pro-
tein-coding variants were inherited, one from each parent.
We identified biallelic variants in FAR1, c.787C>T
(p.Arg263*) and c.1094A>G (p.Asp365Gly), whichwere in-
herited paternally and maternally, respectively. Neither
mutation has been reported in dbSNP or the NHLBI ExomeThe AmericanVariant Server. The candidate variant p.Arg263* introduces
a premature stop codon, and p.Asp365Gly affects a residue
absolutely conserved in 100 vertebrate species and is pre-
dicted to be deleterious by in silico missense prediction
tools SIFT,28 PolyPhen-2,29 and MutationTaster.30
To provide further evidence of pathogenicity for the
variants detected, we sought to model the structure of
the FAR1 reductase domain (residues 1–424), in which all
of the identified variants resided. Molecular modeling of
the p.Glu165_Pro169delinsAsp substitution in family A
showed that amino acids Glu, Val, Val, Tyr, and Pro form
a loop near the active site in the wild-type protein
(Figure 3). A deletion at this position alters the geometry
of the active-site pocket (Figure 3), most likely impairing
enzyme activity. Modeling of p.Arg263* in family B
showed that the alteration, if it does not result in
nonsense-mediated decay, is predicted to affect the entire
domain, including the active center, and is therefore
expected to result in complete loss of enzymatic activity.
Molecular modeling of the p.Asp365Gly substitution
showed that asparagine at position 365 normally forms
stabilizing salt bridges with arginines at positions 263
and 266 (Figure 3). The presence of the p.Asp365Gly
substitution is predicted to disrupt these interactions and
thereby result in destabilization of the tertiary structure
of FAR1 (Figure 3).
To provide a second line of evidence of the functional
effects of the three identified mutations, we determined
the effects of each mutation in a cell-based functional
assay. Because FAR1 reduces both saturated and unsatu-
rated fatty acyl-CoAs of 16 and 18 carbon atoms to their
respective fatty alcohols,24,25 we sought to measure the
enzymatic activity of wild-type and mutation-containing
FAR1 in transfected human embryonic kidney 293
(HEK293) cell lines that were previously shown to have
negligible FAR1 activity in comparison to cells transfected
with plasmids encoding FAR1.24 We also confirmed this in
our experiments (Figure 4). For this, we performed site-
directed mutagenesis to introduce all three mutations—
c.495_507delinsT (p.Glu165_Pro169delinsAsp), c.787C>T
(p.Arg263*), and c.1094A>G (p.Asp365Gly)—into human
FAR1 cDNA (hFAR1) in the pCMV6-XL6 vector. Cells were
transfected with 10 mg of pCMV6-XL6-hFAR1 containing
wild-type or mutation-containing sequences. Forty-eight
hours later, the cells were harvested, and lipids were ex-
tracted with chloroform according to the Bligh and Dyer
method.35 The lipid extracts were silylated and separated
by gas chromatography, and detection was carried out by
electron-impact mass spectrometry.
After transfection with plasmids encoding wild-type
FAR1, levels of hexadecanol and octadecanol in lipid
extracts were elevated (Figure 4), which was expected
given that these are the products of the enzyme after
reduction of palmitic acid and stearic acid, respectively.
Conversely, cells transfected with plasmids encoding
FAR1 containing any of the mutations did not yield
any significant levels of hexadecanol or octadecanolJournal of Human Genetics 95, 602–610, November 6, 2014 605
Figure 3. Molecular Modeling of Amino Acid Substitutions in FAR1
Molecular modeling of the FAR1 reductase domain is based on the crystal structure of the homologous reductase domain from a myco-
bacterial enzyme (Protein Data Bank ID 4DQV31). It was performedwith the programModeler 9.932 and resulted in a structure with good
local geometry and no steric hindrance.
(Center) A model of wild-type FAR1 includes boxes at regions of amino acid substitutions.
(A) A model of wild-type FAR1 shows residues 165–169 (Glu-Val-Val-Tyr-Pro stretch) as blue sticks. The amino acids adopt an extended
conformation and are located in a loop that connects the active-site residues of the enzyme (Thr153 [T153], Tyr204 [Y204], and Lys208
[K208], shown as brown sticks).
(B) The effect of the deletion was modeled with ModLoop,33 and RasMol34 was used for graphical presentation. An amino acid substi-
tution in which the Glu-Val-Val-Tyr-Pro stretch is replaced by a single aspartate (Asp165, shown as a blue stick) is predicted to alter the
geometry of the active-site pocket.
(C) Residue Asp365 (D365) is shown in a space-filled presentation and is colored according to the atom types. Asp365 interacts with
Arg263 (R263) and Arg266 (R266), shown in stick presentation.
(D) Replacement of Asp365 with Gly365 (G365) is predicted to abolish salt bridges with Arg263 (R263) and Arg266 (R266) and thereby
result in a destabilization of the FAR1 structure.(p < 0.05; Figure 4; Figure S1, available online) and were
thus similar to cells transfected with an empty vector.
This result strongly suggests that the presence of any of
these three mutations results in a complete loss of FAR1
activity. This is in accordance with the results of the
measurement of red blood cell plasmalogens of individual
II-1 from family B; they showed significantly decreased
ratios of plasmalogen to fatty acids: 0.002 for C16 (normal
range: 0.079–0.128) and 0.008 for C18 (normal range:
0.199–0.284) (Table 1).36,37
FAR1 is a component of the plasmalogen-biosynthesis
pathway and supplies fatty alcohols for processing by
further enzymes in the peroxisome and ER (Figure 5).24
Impairment of plasmalogen synthesis is the primary
biochemical deficiency present in individuals with
RCDP.2,39 To date, mutations in three genes have been re-
ported to cause RCDP. Specifically, these genes encode the
transporter PEX7, involved in peroxisomal biogenesis,
and the enzymesGNPATandAGPS,which are both directly
involved in plasmalogen synthesis (Figure 5).16–18,25,40606 The American Journal of Human Genetics 95, 602–610, NovembIn individuals with RCDP, fatty alcohols supplied by FAR1
fail to be incorporated into ether lipids, leading to elevated
fatty-alcohol levels and reduced plasmalogen levels.38 The
three alterations we identified essentially abolish FAR1
activity and thus probably lead to lower levels of fatty
alcohols and, as in RCDP, to low plasmalogen levels.
This is supported by our observation that the ratios of
plasmalogen to fatty acids in individual II-1 from family B
were significantly decreased and comparable to those in
persons affected by RCDP (Table 1).36,37
There is a remarkable similarity between the clinical
features of individuals with RCDP and those of the persons
reported here. These features include profound intellectual
disability, congenital cataracts, growth restriction, spas-
ticity, epilepsy, microcephaly, and cerebellar atrophy
(Table 2). However, the most significant difference be-
tween individuals with classical RCDP and individuals
V-1 and V-2 from family A and II-1 from family B is
the absence of rhizomelia and skeletal dysplasia even by
19 years of age. Furthermore, individuals with classicaler 6, 2014
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Figure 4. Results of the FAR1-Activity Assay
Quantification of hexadecanol and octadecanol in lipid extracts
of HEK293 cells transfected with plasmids encoding wild-type
FAR1 (green), plasmids encoding FAR1 with mutations c.495_
507delinsT (p.Glu165_Pro169delinsAsp) (yellow), c.787C>T
(p.Arg263*) (magenta), or c.1094A>G (p.Asp365Gly) (purple), or
an empty vector (blue). Only after transfection with plasmids
encoding wild-type FAR1 could we measure hexadecanol and
octadecanol; all other samples only showed traces. The decrease
in hexadecanol and octadecanol levels was significant (p <
0.05). A detailed description of the methods is provided in the
Figure S1 legend. Error bars represent the SEM.
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Figure 5. Plasmalogen-Biosynthesis Pathway and Associated
Phenotypes
Plasmalogen synthesis is a multistep process that involves several
enzymes. On the luminal side of the peroxisomal membrane,
GNPAT acylates DHAP (dihydroxyacetone phosphate) at its sn-1
position. Then, AGPS is transported into the peroxisome by
PEX7 and uses the 1-acyl-DHAP and the fatty alcohols, which
are supplied by FAR1, as substrates and exchanges the acyl group
for an alkyl group. The resulting 1-o-alkyl DHAP is then reduced
to GPA (1-O-alkyl-2-hydroxy-sn-glycerophosphate) by an acyl/
alkyl-DHAP reductase, which is located in both peroxisomal and
ER membranes. Further processing is similar to the processing of
diacyl glycerophospholipids and takes place in the ER.2,12,15 Muta-
tions in GNPAT and AGPS cause a block in plasmalogen synthesis
and lead to an accumulation of fatty alcohols that are no longer
processed.38 Affected individuals develop RCDP.16,17 Mutations
in PEX7 lead to an absence of peroxisomal AGPS and thus have
similar effects on plasmalogen biosynthesis.18 In individuals V-1
and V-2 from family A and II-1 from family B, fatty acids are no
longer metabolized to fatty alcohols by FAR1, likewise leading to
a decrease in plasmalogen levels and an overlapping phenotype.RCDP usually do not survive the first decade of life. Thus,
we were surprised by the extremely low plasmalogen levels
(similar to those of classical RCDP) in 19-year-old individ-
ual II-1 from family B. The mechanisms underlying these
phenotypic differences are not clear, but we expect that a
kind of tissue-specific compensation mechanism exists.
One possible explanation could be a compensating mech-
anism by FAR2 (fatty acyl-CoA reductase 2), a homolog of
FAR1. FAR2 prefers only saturated C16 and C18 fatty acyl-
CoAs, whereas FAR1 uses both saturated and unsaturated
fatty acyl-CoAs as substrate.24 Nevertheless, given that
the ratios of plasmalogen to fatty acids in red blood cells
of individual II-1 from family B are similar to those ofTable 1. Ratios of Plasmalogen to Fatty Acids
Ratio of C16:0
DMA to C16:0
Fatty Acid
Ratio of C18:0
DMA to C18:0
Fatty Acid
Median Range Median Range
Individual II-1
from family B
0.002 – 0.008 –
Normal control
individuals
(n ¼ 193)
0.103 0.079–0.128 0.241 0.199–0.284
Zellweger spectrum
disorders (n ¼ 125)28
0.014 0.001–0.085 0.042 0.001–0.189
RCDP (n ¼ 53)28 0.002 0.001–0.031 0.002 0.001–0.109
Ratios of plasmalogen to fatty acids were measured for individual II-1 from fam-
ily B and are compared to ratios from healthy individuals and individuals with
plasmalogen-synthesis disorders; the ratios are low and consistent with a defect
in plasmalogen metabolism. DMA stands for dimethyl acetal (of plasmalogen).
The Americanindividuals with classic RCDP, this compensating mecha-
nism would, if at all, be restricted to some tissues. One
further argument against a compensation effect of FAR2
is the expression profile of FAR2, given that according
to the data from GeneHub-GEPIS tissue,41 FAR2 is not
expressed in bones or cartilage, whereas FAR1 is expressed
in both. Another possible explanation is that it has been
proposed that fatty alcohols might be alternatively sup-
plied by b-oxidation.42 However, this is also less likely
because individuals with deficits in peroxisomal b-oxida-
tionmetabolism, such as ACOX1 deficiency (MIM 264470)
and HSD17B4 deficiency (MIM 261515), have normal
plasmalogen levels.2,42 Dietary intake can also be a limited
source of fatty alcohols and might help explain the pheno-
type differences between the individuals presented here
and individuals with RCDP.2
We have identified three FAR1 mutations in two unre-
lated families sharing a number of clinical features that
also clearly overlap those seen in RCDP. These findings
provide evidence that FAR1 deficiency causes a peroxi-
somal disorder as a result of impaired plasmalogen bio-
synthesis. At least seven additional enzymes are involvedJournal of Human Genetics 95, 602–610, November 6, 2014 607
Table 2. Symptoms of RCDP and FAR1 Deficiency
Symptoms
Family A Family B
Individuals with RCDPV-1 V-2 II-1
Profound intellectual disability þ þ þ þ
Neuroregression ? ? þ þþ
Early-onset seizures þ þ þ þ
Spastic quadriparesis þ þ þ þ
Microcephaly þ þ þ þ
Cataracts  þ þ þ
Growth retardation þ þ þþþ þþþ
Chondrodysplasia punctata    þ
Rhizomelia    þþ
Survival alive at 5 years alive at 3 years alive at 19 years demise by 10 years
Brain imaging not available Dandy-Walker
malformation
cerebellar vermis atrophy,
diffuse white-matter disease
cerebral and cerebellar atrophy,
delayed myelination
A comparison of symptoms from individuals with RCDP1, RCDP2, and RCDP3 and the individuals from our families A and B shows a significant overlap in phe-
notypes. Abbreviations are as follows: þ, present; þþ, moderate; þþþ, severe; , not present; and ?, unknown.in plasmalogens biosynthesis, and it is possible that
other yet-to-be-identified mutations in these genes might
account for some unexplained intellectual disability in
combination with congenital cataracts in the general
population. Further genetic analysis will allow for further
delineation of this group of peroxisomal disorders with
disturbed plasmalogen synthesis.Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://dx.doi.org/10.1016/j.ajhg.2014.10.003.Acknowledgments
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